Dynavax Technologies Corporation (DVAX)
Official siteDRUG MANUFACTURERS - SPECIALTY & GENERIC
Last updated: Feb 11, 2026 at 4:00 PM ET
Dynavax Technologies Corporation (DVAX) Financials: Revenue, Profit and Cash Flow
Dynavax Technologies reported revenue of $277.25M for the fiscal year ended Dec 31, 2024, up 19.4% from the year before. That year, net income was $27.31M with a net margin of 9.9%, operating cash flow was $66.51M and free cash flow was $60.16M. The quarter ended Sep 30, 2025 had revenue of $94.88M and net income of $26.93M.
Revenue and Margins
The operating margin was -1.5% in the fiscal year ended Dec 2024. Over the 9 years to Dec 2024, revenue grew from $4.05M, a compound annual rate of 59.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $277.25M | +19.4% | 82.2% | -1.5% | 9.9% |
| Dec 2023 | $232.28M | -67.9% | 78.4% | -15.9% | -2.8% |
| Dec 2022 | $722.68M | +64.5% | 63.7% | 39.2% | 40.6% |
| Dec 2021 | $439.44M | +844.0% | 60.5% | 30.6% | 17.5% |
| Dec 2020 | $46.55M | +32.2% | 75.5% | -146.9% | -161.6% |
| Dec 2019 | $35.22M | +329.6% | 71.1% | -382.9% | -433.3% |
| Dec 2018 | $8.20M | +2407.0% | -33.4% | -1870.2% | -1938.3% |
| Dec 2017 | $327.00K | -97.0% | 100.0% | -29359.3% | -29099.1% |
| Dec 2016 | $11.04M | +172.7% | 100.0% | -1002.5% | -1018.2% |
| Dec 2015 | $4.05M | N/A | 100.0% | -2594.4% | -2636.9% |
Income Statement
In the fiscal year ended Dec 2024, net income turned positive after a loss the year before. In the quarter ended Sep 2025, net income rose 53.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $277.25M | $232.28M | $722.68M | $439.44M | $46.55M | $35.22M | $8.20M | $327.00K | $11.04M | $4.05M |
| Cost of revenue | $49.45M | $50.17M | $262.15M | $173.57M | $11.41M | $10.17M | $10.93M | $0 | $0 | $0 |
| Gross profit | $227.80M | $182.12M | $460.53M | $265.87M | $35.14M | $25.05M | -$2.74M | $327.00K | $11.04M | $4.05M |
| Research and development | $61.55M | $54.89M | $46.60M | $32.23M | $28.61M | $62.33M | $74.95M | $64.99M | $84.49M | $86.94M |
| Operating income | -$4.12M | -$37.03M | $283.52M | $134.49M | -$68.37M | -$134.84M | -$153.32M | -$96.00M | -$110.71M | -$105.07M |
| Net income | $27.31M | -$6.39M | $293.16M | $76.71M | -$75.24M | -$152.60M | -$158.90M | -$95.15M | -$112.44M | -$106.79M |
| EBITDA | N/A | N/A | $287.81M | N/A | -$55.27M | -$121.54M | -$140.40M | -$91.76M | -$108.27M | -$103.05M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.88M | $95.44M | $68.16M | $72.03M | $80.63M | $73.80M | $50.79M | $55.60M | $69.51M | $60.25M | $46.92M | $184.49M |
| Gross profit | $80.47M | $81.41M | $54.40M | $58.62M | $67.55M | $61.81M | $39.82M | $46.91M | $56.28M | $46.71M | $32.21M | $107.00M |
| Operating income | $21.27M | $14.43M | -$23.63M | -$1.63M | $10.08M | $5.20M | -$17.77M | -$8.49M | $5.12M | -$3.40M | -$30.25M | $63.13M |
| Net income | $26.93M | $18.72M | -$96.10M | $7.05M | $17.59M | $11.39M | -$8.72M | $219.00K | $14.29M | $3.43M | -$24.33M | $67.73M |
Balance Sheet
As of Dec 2024, total debt of $223.85M exceeded cash and equivalents by $127.97M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $986.26M | $997.10M | $985.85M | $1.04B | $353.27M | $279.07M | $210.88M | $218.78M | $109.68M | $216.63M |
| Current assets | $848.94M | $859.12M | $916.99M | $972.52M | $290.01M | $208.65M | $174.36M | $198.02M | $89.60M | $199.95M |
| Cash and equivalents | $95.88M | $150.28M | $202.00M | $436.19M | $32.07M | $39.88M | $49.35M | $26.58M | $24.29M | $44.81M |
| Total liabilities | $389.46M | $375.02M | $404.84M | $816.87M | $294.58M | $270.78M | $147.82M | $19.24M | $20.48M | $29.55M |
| Short-term debt | $0 | $4.50M | $3.63M | $2.58M | $3.25M | $3.04M | N/A | N/A | N/A | N/A |
| Long-term debt | $223.85M | $222.70M | $221.58M | $220.49M | $179.81M | $178.60M | $100.87M | $0 | $0 | $0 |
| Shareholder equity | $596.80M | $622.07M | $581.01M | $222.37M | $58.69M | $8.29M | $63.06M | $199.55M | $89.20M | $187.08M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $946.51M | $918.45M | $945.93M | $986.26M | $1.06B | $1.02B | $986.57M | $997.10M | $972.93M | $936.43M | $969.92M | $985.85M |
| Total liabilities | $412.37M | $424.29M | $414.99M | $389.46M | $380.56M | $373.47M | $368.08M | $375.02M | $368.02M | $359.23M | $406.19M | $404.84M |
| Cash and equivalents | $160.25M | $99.10M | $51.72M | $95.88M | $119.33M | $112.50M | $132.03M | $150.28M | $154.51M | $226.82M | $174.35M | $202.00M |
| Shareholder equity | $534.14M | $494.16M | $530.94M | $596.80M | $681.43M | $642.85M | $618.48M | $622.07M | $604.92M | $577.21M | $563.73M | $581.01M |
Cash Flow
In the fiscal year ended Dec 2024, free cash flow was 90.5% of operating cash flow. Share repurchases came to 166.2% of it.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $66.51M | $100.56M | $62.72M | $335.53M | -$92.25M | -$121.25M | -$131.30M | -$77.52M | -$107.05M | -$92.56M |
| Capital expenditures | $6.35M | $4.10M | $7.14M | $9.48M | $4.07M | $22.40M | $4.19M | $669.00K | $7.76M | $6.97M |
| Free cash flow | $60.16M | $96.46M | $55.58M | $326.05M | -$96.32M | -$143.65M | -$135.49M | -$78.19M | -$114.81M | -$99.53M |
| Share repurchases | $100.00M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$18.04M | -$153.93M | -$316.00M | $14.22M | -$26.53M | -$42.78M | $55.47M | -$108.70M | $86.25M | -$85.80M |
| Financing cash flow | -$102.02M | $1.39M | $19.52M | $55.78M | $109.50M | $154.35M | $99.07M | $187.84M | $531.00K | $173.96M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $33.83M | $23.43M | -$19.64M | $53.01M | $19.47M | $10.71M | -$16.68M | $13.77M | $31.13M | $28.05M | $27.62M | $34.95M |
| Capital expenditures | $1.24M | $1.45M | $3.93M | $3.48M | $1.35M | $779.00K | $749.00K | $1.72M | $347.00K | $751.00K | $1.28M | $1.59M |
| Free cash flow | $32.59M | $21.98M | -$23.57M | $49.53M | $18.12M | $9.93M | -$17.43M | $12.04M | $30.78M | $27.30M | $26.34M | $33.36M |
Frequently Asked Questions About DVAX
What is Dynavax Technologies' annual revenue?
Dynavax Technologies reported revenue of $277.25M for the fiscal year ended Dec 31, 2024.
How fast is Dynavax Technologies' revenue growing?
Revenue was up 19.4% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -14.2%.
Is Dynavax Technologies profitable?
Yes. Dynavax Technologies reported net income of $27.31M for the fiscal year ended Dec 31, 2024, with a net margin of 9.9%.
How much free cash flow does DVAX generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of $66.51M minus capital expenditures of $6.35M produced free cash flow of $60.16M.
How much debt does Dynavax Technologies have?
The balance sheet dated Dec 31, 2024 reported long-term debt of $223.85M, short-term debt of $0 and cash and equivalents of $95.88M.
DVAX pages: Overview, Financials